List of Excipients in Branded Drug EDLUAR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	EDLUAR	zolpidem tartrate	0037-6050	CELLULOSE, MICROCRYSTALLINE
Viatris Specialty LLC	EDLUAR	zolpidem tartrate	0037-6050	CROSCARMELLOSE SODIUM
Viatris Specialty LLC	EDLUAR	zolpidem tartrate	0037-6050	MAGNESIUM STEARATE
Viatris Specialty LLC	EDLUAR	zolpidem tartrate	0037-6050	MANNITOL

Edluar Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 31, 2026

Edluar is a 5 mg and 10 mg zolpidem tartrate sublingual tablet approved by the FDA for short-term treatment of insomnia characterized by difficulty initiating sleep. Its formulation uses a rapidly disintegrating, low-dose solid dosage platform with mannitol, silicified microcrystalline cellulose, sucralose, crospovidone, colloidal silicon dioxide, and magnesium stearate. The principal commercial opportunity is not a simple tablet copy. It is a differentiated oral-transmucosal product that improves onset, portability, dose flexibility, or tolerability while avoiding unnecessary formulation complexity.

What is Edluar and how does its sublingual formulation work?

Edluar contains zolpidem tartrate, a nonbenzodiazepine hypnotic that acts at the benzodiazepine site of the GABA-A receptor complex. The product is placed under the tongue and allowed to disintegrate without water. FDA labeling identifies 5 mg and 10 mg strengths and limits use to short-term insomnia treatment in adults. Edluar is a Schedule IV controlled substance in the United States. [1]

The dosage form is designed for rapid tablet breakup and dissolution in a small volume of saliva. The formulation must balance several competing requirements:

• Fast wetting and disintegration.
• Acceptable sublingual taste.
• Low tablet mass.
• Adequate mechanical strength for packaging and handling.
• Limited friability during transport.
• Consistent zolpidem delivery across saliva volumes.
• Low residual sensation after administration.

The formulation does not depend on a conventional swallowed immediate-release tablet profile. Its value proposition is the administration route and patient convenience rather than a fundamentally different active pharmaceutical ingredient.

What excipients does Edluar contain?

The Edluar inactive-ingredient system is reported in FDA labeling as containing mannitol, silicified microcrystalline cellulose, sucralose, crospovidone, colloidal silicon dioxide, and magnesium stearate. [1]

Excipient	Likely formulation function	Commercial relevance
Mannitol	Diluent, mouthfeel modifier, cooling sensation	Supports palatability and rapid dissolution
Silicified microcrystalline cellulose	Binder and structural aid	Improves tablet strength in a low-mass orally disintegrating system
Sucralose	High-intensity sweetener	Masks zolpidem bitterness
Crospovidone	Superdisintegrant	Promotes rapid tablet breakup
Colloidal silicon dioxide	Glidant and processing aid	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces tooling friction and tablet ejection problems

The combination indicates a conventional direct-compression or low-moisture tablet strategy. That is commercially significant because zolpidem tartrate is a potent, low-dose active. Excipient selection must support content uniformity without creating excessive tablet bulk or slowing dissolution.

Why mannitol is important in Edluar

Mannitol is widely used in orally disintegrating and orally dissolving tablets because it provides a relatively clean mouthfeel and can contribute a cooling sensation during dissolution. For a sublingual product, that sensory profile can improve acceptance compared with less soluble polyols or highly hygroscopic fillers.

Mannitol also helps position the formulation as a premium patient-experience product. Its limitations include potential brittleness, dependence on particle engineering, and the need to control polymorphic and particle-size characteristics. A generic or follow-on product that changes mannitol grade may preserve the label composition while altering hardness, disintegration time, dissolution, and mouthfeel.

Why crospovidone and silicified microcrystalline cellulose matter

Crospovidone provides rapid liquid uptake and swelling or wicking without requiring a large concentration of disintegrant. Silicified microcrystalline cellulose contributes compactability and flow, which are important when the tablet must be strong enough for commercial packaging but still disintegrate rapidly under the tongue.

The excipient interaction is more important than any single ingredient. Increasing magnesium stearate can improve manufacturability but may reduce wetting. Increasing compression force can improve hardness but delay disintegration. Increasing crospovidone can accelerate breakup but may affect tablet texture and friability.

What excipient strategies could improve Edluar or support a competing product?

The strongest product-development opportunities are in taste, disintegration, moisture control, and dose personalization.

Taste-masking systems

Zolpidem has a bitter pharmaceutical taste. Sucralose provides sweetness but may not fully suppress bitterness in all patients. A competing product could investigate:

• Sucralose combined with acesulfame potassium or steviol glycosides.
• Ion-exchange resin complexes.
• Cyclodextrin inclusion systems.
• Polymer-based taste-masking coatings.
• pH-modifying microenvironments.
• Flavor systems compatible with sublingual use.

A taste-masking approach must not create a slow-dissolving barrier or reduce mucosal availability. It also must avoid excipient levels that create an undesirable aftertaste or interfere with zolpidem release.

Fast-disintegration platforms

A follow-on product could use coprocessed excipients, spray-dried mannitol, crospovidone grades with higher capillary uptake, or porous carrier systems. These technologies may reduce disintegration time without adding a complex manufacturing step.

Potential differentiation claims include:

• Shorter in-mouth disintegration time.
• Lower residual tablet mass.
• Improved dissolution under low-saliva conditions.
• Better robustness after exposure to humidity.
• Lower tablet friability at equivalent disintegration performance.

Any performance claim would require comparative dissolution, disintegration, stability, and clinical or human-factors support where the claim affects labeling.

Moisture-resistant packaging and excipient control

Mannitol-based orally disintegrating tablets can be sensitive to mechanical damage and environmental exposure even when the formulation is not highly hygroscopic. Commercial protection may rely on unit-dose blister packaging, high-barrier films, desiccants, or improved tablet strength.

Packaging is a material opportunity because a formulation that performs well in laboratory testing can fail during shipment or patient handling. A product using the same active and similar excipients may gain a market advantage through:

• Aluminum-aluminum blister packaging.
• Child-resistant unit-dose systems.
• Calendarized adherence packs.
• Hospital and institutional dispensing formats.
• Portable packaging optimized for nighttime use.

Packaging claims may be easier to protect than a basic mannitol-crospovidone composition if the product has a distinct moisture-control or dose-dispensing configuration.

How does Edluar compare with conventional zolpidem tablets?

Attribute	Edluar	Conventional immediate-release zolpidem tablet
Active ingredient	Zolpidem tartrate	Zolpidem tartrate
Administration	Sublingual	Oral, swallowed
Available strengths	5 mg and 10 mg	Commonly 5 mg and 10 mg
Water required	No	Usually taken with water
Primary differentiation	Administration route and fast oral disintegration	Established low-cost tablet platform
Excipient priority	Mouthfeel, rapid disintegration, taste	Swallowability, dissolution, content uniformity
Commercial barrier	Sublingual performance and palatability	Price and generic competition
Main risk	Limited differentiation from other zolpidem products	Commodity pricing and substitution

Edluar competes against generic oral zolpidem, extended-release zolpidem products, zolpidem oral sprays, and other insomnia medicines. Its commercial position depends on whether patients, prescribers, payers, or institutions value sublingual administration enough to support a price premium.

What patents protect Edluar and when does it lose exclusivity?

Edluar was approved under NDA 022038 in March 2009. [1] The product’s original protection was associated with sublingual zolpidem technology and related formulation or delivery claims. Patent protection for an approved drug must be assessed through current USPTO records, FDA Orange Book listings, terminal disclaimers, patent-term adjustments, and any litigation or settlement history. Patent expiry should not be inferred from the 2009 approval date alone.

The commercially relevant protection categories are:

1. Sublingual zolpidem compositions.
2. Rapidly disintegrating tablet structures.
3. Taste-masked zolpidem formulations.
4. Methods of treating insomnia using sublingual zolpidem.
5. Packaging or moisture-protection systems.
6. Manufacturing processes for low-dose content uniformity.

The Orange Book is the controlling public source for patents submitted by an NDA holder and listed as covering the approved product. [2] A patent may protect a formulation or method of use without preventing all alternative zolpidem products from entering the market.

What is the Orange Book status of Edluar and what generic entry risks exist?

The main generic pathway is an abbreviated new drug application, or ANDA, demonstrating pharmaceutical equivalence and bioequivalence to Edluar. A generic applicant may pursue:

• Paragraph I certification if no relevant patent is listed.
• Paragraph II certification if listed patents have expired.
• Paragraph III certification with launch after patent expiry.
• Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.

The key technical issue is whether the applicant can match the sublingual dosage form and demonstrate bioequivalence using FDA-accepted pharmacokinetic endpoints. The applicant does not necessarily need to use Edluar’s exact excipients. A different excipient system may be used if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements.

Generic entry risks are highest where:

• Listed patents have expired or are absent.
• The product has no meaningful formulation patent beyond the active ingredient.
• The generic can use standard orally disintegrating tablet technology.
• The reference product has limited payer differentiation.
• The generic demonstrates equivalent exposure without reproducing the precise excipient composition.

The risk is lower where the patent estate includes enforceable sublingual performance claims, where the dosage form is difficult to reproduce, or where the reference product has strong product-specific prescribing demand.

Which companies could challenge Edluar or compete in sublingual zolpidem?

Competition can arise from several groups:

• Generic pharmaceutical companies with ANDA capabilities.
• Specialty CNS companies developing orally disintegrating or transmucosal products.
• Contract development and manufacturing organizations with fast-dissolving tablet platforms.
• Companies licensing taste-masking or oral-mucosal delivery technologies.
• Manufacturers of competing insomnia therapies, including dual orexin receptor antagonists and melatonin-receptor products.

The most credible competitor does not need to copy Edluar’s full composition. It needs a manufacturable zolpidem product with acceptable taste, rapid disintegration, consistent exposure, and a lower cost of goods.

What licensing deals and commercial partnerships are relevant?

The commercial value of Edluar-related technology is likely to sit in platform licensing rather than in a single excipient. Potential licensing targets include:

• Fast-disintegrating tablet technology.
• Taste-masking systems for bitter CNS drugs.
• Sublingual absorption enhancers.
• High-barrier unit-dose packaging.
• Pediatric and geriatric dosage-form technologies.
• Manufacturing processes for low-dose, content-uniform tablets.

A deal structure could include an upfront payment, development milestones, manufacturing supply obligations, and royalties on net sales. A formulation platform with applications across sedatives, analgesics, antiemetics, and rescue medicines may attract more licensing interest than an Edluar-specific composition.

How strong is the Edluar patent estate?

Patent strength depends on claim scope, remaining term, validity, and the number of non-infringing formulation routes. A narrow composition claim covering a specific excipient ratio may be easier to design around than a broader claim covering rapid sublingual delivery of zolpidem.

A stronger estate would include independent claims covering:

• The active ingredient and sublingual administration.
• A defined disintegration threshold.
• Pharmacokinetic performance.
• Taste-masking architecture.
• Moisture-stable packaging.
• Manufacturing controls that are difficult to replicate.

A weaker estate would rely primarily on standard excipients, broad method-of-use language, or patents nearing expiry. The absence of a composition patent does not eliminate commercial value, but it shifts protection toward brand recognition, regulatory exclusivity, manufacturing know-how, packaging, and payer positioning.

What FDA exclusivity and regulatory barriers apply to Edluar?

Edluar’s approval was based on an NDA rather than a biologics license application. Biosimilar competition is therefore not relevant. The relevant competitive pathway is generic substitution through ANDAs or, depending on product differences, a 505(b)(2) application.

Potential 505(b)(2) opportunities include:

• A new sublingual zolpidem strength.
• A modified-release or altered-exposure profile.
• A new taste-masking formulation.
• A new delivery device or oral-mucosal presentation.
• A pediatric or geriatric formulation with supporting clinical data.

FDA regulatory risk includes controlled-substance requirements, abuse and misuse labeling, dose-related next-morning impairment, sex-specific dosing considerations, and the need to maintain zolpidem exposure within an established safety range. [1,3]

What are the main commercial opportunities for Edluar excipients?

The most attractive opportunities are:

1. Premium generic Edluar with improved taste and equivalent pharmacokinetics.
2. Lower-cost generic Edluar using coprocessed mannitol and cellulose systems.
3. Pediatric or geriatric sublingual zolpidem development, subject to safety and regulatory feasibility.
4. Unit-dose packaging for hospitals, long-term-care facilities, and travel use.
5. Excipient platform licensing for other bitter, low-dose CNS compounds.
6. Reformulation into a lower-dose product aligned with current zolpidem safety concerns.
7. Manufacturing partnerships focused on direct compression, humidity control, and high-throughput blister packaging.

Revenue exposure depends on product availability, payer coverage, generic timing, and the extent to which clinicians view sublingual administration as clinically meaningful. A lower-cost generic is likely to pressure price rapidly unless the manufacturer preserves a differentiated package, distribution channel, or formulation profile.

Key Takeaways

• Edluar is a 5 mg and 10 mg zolpidem tartrate sublingual tablet approved under NDA 022038.
• Its reported excipients are mannitol, silicified microcrystalline cellulose, sucralose, crospovidone, colloidal silicon dioxide, and magnesium stearate.
• The formulation’s commercial value comes from rapid disintegration, taste management, and water-free administration.
• The main follow-on opportunities are taste masking, faster disintegration, improved moisture protection, unit-dose packaging, and lower-cost manufacturing.
• Generic competition is more likely to focus on pharmaceutical equivalence and bioequivalence than on duplicating every excipient.
• Biosimilar risk does not apply because zolpidem is a small-molecule drug.
• The most defensible future patent claims would cover delivery performance, taste-masking architecture, packaging, and manufacturing controls rather than standard excipient combinations alone.

FAQs About Edluar Excipient Strategy and Commercial Potential

Can a generic Edluar use different excipients?

Yes. An ANDA applicant generally does not need to replicate the reference product’s inactive ingredients exactly, provided the product meets applicable FDA requirements for pharmaceutical equivalence, quality, labeling, and bioequivalence.

Is Edluar an orally disintegrating tablet or a sublingual tablet?

Edluar is labeled as a sublingual tablet. It is placed under the tongue and allowed to disintegrate without water. This distinguishes it from a conventional swallowed zolpidem tablet.

Which excipient is most important for Edluar taste?

Sucralose is the primary listed sweetener, while mannitol contributes mouthfeel and a cooling sensation. Neither necessarily eliminates all zolpidem bitterness, creating an opportunity for improved taste-masking technology.

Can Edluar be developed through the 505(b)(2) pathway?

A materially different zolpidem product, such as a new dosage form, strength, delivery system, or pharmacokinetic profile, could potentially use a 505(b)(2) application. The applicable pathway depends on the proposed product and supporting data.

What is the largest manufacturing challenge for an Edluar follow-on product?

The central challenge is balancing rapid sublingual disintegration with tablet strength, low-dose content uniformity, taste acceptability, and moisture resistance. Changes in lubricant level, compression force, excipient grade, or packaging can affect all four properties.

References

1. U.S. Food and Drug Administration. (2009). Edluar (zolpidem tartrate) sublingual tablets prescribing information. NDA 022038.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia